CervoMed (CRVO) Long-Term Debt Repayments (2017 - 2018)

CervoMed (CRVO) posted Long-Term Debt Repayments of $600000.0 for Q2 2018, down 68.42% sequentially from $1.9 million in Q3 2017.

CervoMed (CRVO) Long-Term Debt Repayments (2017 - 2018) Analysis & Trends

CervoMed has reported Long-Term Debt Repayments for 2 years, with the latest figure at $600000.0 in Q2 2018.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $600000.0 in Q2 2018, while the trailing twelve-month figure through Dec 2018 was $2.5 million (changed N/A YoY) and the FY2018 annual result came in at $550000.0, down 70.74% from the prior year.
Long-Term Debt Repayments declined to $600000.0 in Q2 2018 per CRVO's latest filing, from $1.9 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $1.9 million in Q3 2017 and troughed at $600000.0 in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	17.05 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-10.01 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	CervoMed	26.64 Mn	26.64 Mn	-	-

Download Data